FDA's ORAL VERAPAMIL ANDA APPROVALS ON EVE OF EXCLUSIVITY EXPIRATION PIT FIVE GENERIC PRODUCTS v. CALAN, ISOPTIN; INDERAL, REGLAN INDICATIONS NO LONGER EXCLUSIVE

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".